PubMed:24403068 / 464-652 JSONTXT

{"project":"PubMed_ArguminSci","denotations":[{"id":"T4","span":{"begin":0,"end":83},"obj":"DRI_Outcome"},{"id":"T5","span":{"begin":100,"end":188},"obj":"DRI_Outcome"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"sentences","denotations":[{"id":"T5","span":{"begin":0,"end":188},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"DisGeNET","denotations":[{"id":"T6","span":{"begin":19,"end":28},"obj":"gene:5552"},{"id":"T7","span":{"begin":126,"end":128},"obj":"disease:C0026764"},{"id":"T8","span":{"begin":19,"end":28},"obj":"gene:5552"},{"id":"T9","span":{"begin":155,"end":187},"obj":"disease:C0085110"}],"relations":[{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"PubmedHPO","denotations":[{"id":"T3","span":{"begin":129,"end":134},"obj":"HP_0002664"},{"id":"T4","span":{"begin":155,"end":187},"obj":"HP_0004430"},{"id":"T5","span":{"begin":162,"end":187},"obj":"HP_0005387"},{"id":"T6","span":{"begin":171,"end":187},"obj":"HP_0002721"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"24403068-4#19#28#gene5552","span":{"begin":19,"end":28},"obj":"gene5552"},{"id":"24403068-4#155#187#diseaseC0085110","span":{"begin":155,"end":187},"obj":"diseaseC0085110"}],"relations":[{"id":"19#28#gene5552155#187#diseaseC0085110","pred":"associated_with","subj":"24403068-4#19#28#gene5552","obj":"24403068-4#155#187#diseaseC0085110"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"mondo_disease","denotations":[{"id":"T6","span":{"begin":126,"end":128},"obj":"Disease"},{"id":"T7","span":{"begin":129,"end":134},"obj":"Disease"},{"id":"T8","span":{"begin":155,"end":187},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0009693"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0015974"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T6","span":{"begin":126,"end":128},"obj":"Phenotype"},{"id":"T7","span":{"begin":129,"end":134},"obj":"Phenotype"},{"id":"T8","span":{"begin":155,"end":187},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"HP:0006775"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"HP:0002664"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"HP:0004430"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T6","span":{"begin":126,"end":128},"obj":"Disease"},{"id":"T7","span":{"begin":129,"end":134},"obj":"Disease"},{"id":"T8","span":{"begin":155,"end":187},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0009693"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0015974"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"GlyCosmos15-NCBITAXON","denotations":[{"id":"T1","span":{"begin":145,"end":149},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"10088"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"sentences","denotations":[{"id":"T5","span":{"begin":0,"end":188},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T5","span":{"begin":0,"end":188},"obj":"Sentence"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":145,"end":149},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"10088"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}

{"project":"HP-phenotype","denotations":[{"id":"T6","span":{"begin":126,"end":128},"obj":"Phenotype"},{"id":"T7","span":{"begin":129,"end":134},"obj":"Phenotype"},{"id":"T8","span":{"begin":155,"end":187},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"HP:0006775"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"HP:0002664"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"HP:0004430"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency."}